SCHEMBL21153028

SCHEMBL21153028

COc1ccc(C#Cc2cccc(N/N=N/c3ccc(C(N)N)cc3)c2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.40
RAB9A P51151 7/20 0.40
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
SMN1; SMN2 Q16637 3/20 0.38
MAPT P10636 2/20 0.38
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA9 Q16790 2/20 0.37
ACACB O00763 2/20 0.37
APP P05067 2/20 0.37
KCNH2 Q12809 1/20 0.36
PTGES O14684 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 1/20 0.35
CYP1B1 Q16678 2/20 0.35
CYP1A1 P04798 1/20 0.33
TSHR P16473 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17469670 0.83 FURIN (0.52) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL21152016 0.74 ACACB (0.35) NPC1RAB9AMEN1KMT2AACACB
SCHEMBL17469666 0.69 TMPRSS2 (0.61) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL22062054 0.69 SIGMAR1 (0.53) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL22062151 0.69 NPC1 (0.71) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL17469657 0.68 TMPRSS2 (0.56) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL702612 0.66 CA12 (0.66) CA12CA1CA2CA9APP
SCHEMBL17469614 0.65 APP (0.67) SMN1; SMN2MAPTCA12CA1CA2
SCHEMBL22062047 0.64 CYP1B1 (0.55) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL9190350 0.64 APP (0.47) NPC1RAB9AMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190209548-A1 LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME UNIVERSITY OF MARYLAND, BALTIMORE 2019-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190209548-A1 LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME MCL1, DPYD, TOP2B NPC1 1776/4885RAB9A 1465/4885MEN1 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.